OPC-108459

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd.

Conditions

Atrial FibrillationParoxysmal Atrial FibrillationPersistent Atrial Fibrillation

Phase 1

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

TerminatedNCT01483183

Otsuka Pharmaceutical Development & Commercialization, Inc.Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Start: 2011-11-30End: 2015-10-31Updated: 2017-04-10

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

CompletedNCT02069119

Otsuka Pharmaceutical Co., Ltd.Atrial Fibrillation

Start: 2014-02-28End: 2015-08-31Updated: 2018-11-05